Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
NCT03626727 · Brigham and Women's Hospital · EARLY_PHASE1 · withdrawn · last registry update 2021-03-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Target study population was extremely difficult to recruit and planned study budget was exceeded” | – | Registry record, Brigham and Women's Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-01-05Phase 3 first posted: RVL Pharmaceuticals, Inc., Arbaclofen + Placebo (NCT05179577)
- 2021-11-24Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Acamprosate + Lovastatin (NCT02998151)
- 2021-10-26Phase 3 first posted: Tasly GeneNet Pharmaceuticals Co., Ltd, PXT3003 + PXT3003 placebo (NCT05092841)
- 2021-04-27Results posted on the registry: Vanderbilt University, Baclofen bolus injection (NCT02903823)
- 2021-03-23Results posted on the registry: Centre for Addiction and Mental Health, Xyrem (NCT02637076)
- 2021-02-21Phase 3 first posted: Pharnext S.C.A., (RS)-baclofen, naltrexone hydrochloride and D-sorbitol + Placebo (NCT04762758)
- 2020-11-18Results posted on the registry: Imperial College London, Sodium Oxybate (NCT02055898)
- 2020-11-12Results posted on the registry: Jazz Pharmaceuticals, JZP-258 (NCT03030599)
- 2020-08-12Results posted on the registry: Montefiore Medical Center, Metaxalone + Tizanidine (NCT03068897)
- 2020-06-30Phase 3 first posted: Avadel, FT218 (NCT04451668)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision